Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin

0191662 - UMG-J 20033173 RIV GR eng J - Journal Article
Indrová, Marie - Bubeník, Jan - Mikyšková, Romana - Vonka, V. - Šmahel, M. - Žák, R. - Šímová, Jana - Bieblová, Jana - Mendoza, Luis - Jandlová, Táňa
Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
International Journal of Oncology. Roč. 2002, č. 20 (2002), s. 643-646. ISSN 1019-6439. E-ISSN 1791-2423
Institutional research plan: CEZ:AV0Z5052915
Keywords : HPV16, IL-2 * tumour vaccines * gene therapy
Subject RIV: EB - Genetics ; Molecular Biology
Impact factor: 2.931, year: 2002

Oncogenic, moderately immunogenic, MHC class I- and class II-, B7(-), MK16/l/III ABC (MK16) cells were previously established by co-transfection of HPV16 E6/E7 and activated H-ras oncogene DNA into C57BL/6 kidney cells. Subcutaneous transplantation of these cells produced progressively growing local neoplasms which metastasized spontaneously to lungs and lymph nodes. The MK16 cells were implanted into syngeneic mice and used to examine whether the tumour lacking the signal molecules required for the induction of and sensitivity to T cell immunity is susceptible to local IL-2 treatment and IL-2 gene therapy. Peritumoural administration of human rIL-2 or murine IL-2 gene-modified MK16 tumour vaccine inhibited growth of subcutaneous MK16 tumour transplants and reduced the number of their lung metastases. These results indicate that experimental tumours which are MHC class I- and mimick in this respect a high proportion of human HPV16-associated carcinomas are suitable for IL-2 treatment.
Permanent Link: http://hdl.handle.net/11104/0087400